Etienne Gaudette

Étienne Gaudette, PhD, is a senior health economist at the Ontario Ministry of Health and Long-Term Care, an adjunct research professor at the Department of Pharmaceutical and Health Economics in the USC School of Pharmacy, and a health economist at the USC Keck-Schaeffer Initiative for Population Health Policy. He was previously a research assistant professor at the USC School of Pharmacy and policy director at the USC Roybal Center for Health Policy Simulation.

Gaudette’s research focuses on health economics, the economics of aging, microsimulation methods and applied macroeconomics. He is interested in the power of structures and incentives to influence decisions that, when aggregated, produce demand for care, and he collaborates with healthcare professionals to ensure the real-world impact of his work. He works with neurologists in the multi-institutional Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) study group to assess the impact of triage decisions and follow-up care for the economic well-being of patients after TBI.

His research has been published in renowned health economics journals including PharmacoEconomics and Value in Health, as well as medical journals such as Medical Care and American Journal of Preventive Medicine.

Gaudette earned a BSc and MSc in economics from the Université de Sherbrooke and a PhD in economics from the Université du Québec à Montréal.

Recent Work

PCSK9 Inhibitors Show Value for Patients and the US Health Care System

Schaeffer Center researchers estimate the long-term health and economic value of PCSK9 inhibitors for Americans (51 years and older).

Lifetime Consequences of Early-Life and Midlife Access to Health Insurance: A Review

The researchers reviewed 112 experimental or quasi-experimental studies on the effects of health insurance prior to people becoming eligible for Medicare on a broad set of outcomes.

Using Self Reports or Claims to Assess Disease Prevalence

Patricia St. Clair and her colleagues assess prevalence of diabetes and heart attack in the US elderly population across the most well used data sources for estimation.

The Long-Term Benefits of Increased Aspirin Use by At-Risk Americans Aged 50 and Older

The study finds increased aspirin use by high-risk older Americans would generate $692 billion in net health benefits by 2036.

Competing Risks: Investing in Sickness Rather Than Health

The authors contend that the time has come for the US to distance itself from the rhetoric and colored ribbons of conquering individual diseases to begin a real discussion about how best to help Americans achieve longer, healthier, and more productive lives.